e-learning
resources
ERJ
2015
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Linezolid in drug-resistant tuberculosis: haste makes waste
Hughes Jennifer, Isaakidis Petros, Andries Aristomo, Mansoor Homa, Cox Vivian, Meintjes Graeme, Cox Helen
Source:
Eur Respir J 2015; 46: 1844-1846
Journal Issue:
December
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Hughes Jennifer, Isaakidis Petros, Andries Aristomo, Mansoor Homa, Cox Vivian, Meintjes Graeme, Cox Helen. Linezolid in drug-resistant tuberculosis: haste makes waste. Eur Respir J 2015; 46: 1844-1846
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India
Source: Eur Respir J 2012; 39: 956-962
Year: 2012
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Source: Eur Respir J 2016; 48: 582-585
Year: 2016
Linezolid in multidrug-resistant tuberculosis treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 485s
Year: 2004
Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?
Source: Eur Respir J 2008; 31: 904-905
Year: 2008
Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience
Source: Eur Respir J 2016; 47: 333-336
Year: 2016
Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient
Source: Eur Respir J 2014; 43: 292-294
Year: 2004
What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis?
Source: Eur Respir J 2009; 34: 1492-1494
Year: 2009
Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis
Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020
Year: 2021
Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?
Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017
Year: 2017
Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?
Source: Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019
Year: 2020
Mefloquine as a potential drug against multidrug-resistant tuberculosis
Source: Eur Respir J 2015; 46: 1503-1505
Year: 2015
Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary?
Source: Eur Respir J, 54 (4) 1901494; 10.1183/13993003.01494-2019
Year: 2019
Multidrug- and extensively drug-resistant tuberculosis: an emerging threat
Source: Eur Respir Rev 2009; 18: 195-197
Year: 2009
Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis
Source: Eur Respir J 2015; 46: 444-455
Year: 2015
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Fluoroquinolone resistance in multidrug-resistant
Mycobacterium tuberculosis
independent of fluoroquinolone use
Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017
Year: 2017
Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required?
Source: Eur Respir J 2013; 42: 1148-1150
Year: 2013
Clinical and operational value of the extensively drug-resistant tuberculosis definition
Source: Eur Respir J 2007; 30: 623-626
Year: 2007
Extensively drug-resistant tuberculosis: back to the future
Source: Eur Respir J 2010; 36: 475-477
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept